Brisa Concessão Rodoviária. 1Q 2017 Traffic Update

Size: px
Start display at page:

Download "Brisa Concessão Rodoviária. 1Q 2017 Traffic Update"

Transcription

1 Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017

2 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according to its nature, it is not provisional and which is not intended to give any forward-looking statements, estimates or future projections and should be read accordingly. The Information is publicly disclosed under the applicable rules and regulations and may be freely used under the condition that it shall remain unchanged. BCR renders no representation, warranty or undertaking, express or implied, with respect to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness thereof. Neither BCR nor any of its affiliates, subsidiaries, directors, representatives, employees and/or advisors shall not be held liable nor responsible for any direct or indirect damages whatsoever that may occur or that may arise from any use of the Information or otherwise arising in connection with this presentation or as a result of any use or manipulation, modification or alteration, update, revision or correction, whether intentional or not, of such information the Information. All data referred in this document must be reported to the document s date. Therefore, considering the nature and objective of the disclosure of the Information, BCR shall not be under any obligation to update said Information, nor shall it be under any obligation to make any prior announcement of any amendment or modification thereof its contents and therefore the Information may not be used in the future in connection with any offer (public or private) in relation to securities issued by BCR. Any decision to purchase, subscribe, exchange or otherwise trade any securities in any offering launched by BCR or on its behalf should be made solely on the basis of the information to be contained in the relevant prospectus, base prospectus or offering memorandum to be made available in due course in relation to any such offering in accordance with the applicable rules and regulations. The Information herein is provided for general purposes only and is not intended to constitute professional advice. Furthermore, the Information does not constitute or form part of and should not be construed as, an offer (public or private) to sell, issue, advertise, market, invite to subscribe, submit to investment gathering procedures or the solicitation of an offer (public or private) to buy or acquire securities of BCR or any of its affiliates in any jurisdiction or an inducement to enter into investment activity in any jurisdiction. Use of data contained herein in its original format shall contain a quote as to the source of the information and/or a reference of where it was taken from. BRISA Concessão Rodoviária, S.A. Head-Office: Quinta da Torre da Aguilha, Edifício BRISA, São Domingos de Rana Share capital: EUR Registered in the Commerce Registry Office of Cascais under register and corporate tax number Q 2017 Traffic update, 15 th May

3 Traffic Update 1Q 2017 analysis Quarterly ADT * (Average Daily Traffic) Quarterly VKM growth Q % % Q16 3Q16 4Q % +6.9% +6.6% +7.0% 1Q 2Q 3Q 4Q * ADT does not include negative leap year effect Q Q % Traffic mix 6.2% 93.8% LV/HV traffic growth (yoy) 12.4% 3.9% 1Q 2017 hampered by Easter effect (in 2016 Easter occurred on the 1Q, while in 2017 Easter was in April) and by leap year effect +3.3% Positive traffic performance continued during 1Q Q 2017 Traffic update, 15 th May

4 Traffic Update 1Q 2017 analysis VKM Growth Breakdown (cumulative) Q 16 2Q 16 3Q 16 4Q 16 1Q 17 ADT (organic) 6.7% 6.2% 6.0% 6.2% 6.5% Organic growth with a sound performance Calendar effect 2.0% 0.6% 0.8% 0.5% -2.3% 1Q17 hampered by Easter calendar effect Others 1.2% 0.5% 0.3% 0.3% -0.9% 1Q17 with a negative effect from leap year Total 9.9% 7.3% 7.1% 7.0% 3.3% 10% Breakdown of 1Q17 Traffic Growth (VKM) Organic growth Calendar effect Others 5% 0% 6.7% 6.2% 6.0% 6.2% 6.5% 6.5% -2.3% -0.9% 3.3% -5% 1Q16 2Q16 3Q16 4Q16 1Q17 Organic growth Calendar effect Others Total VKM Despite a steady organic traffic growth, 1Q 2017 was negatively affected by Easter and Leap year effects 1Q 2017 Traffic update, 15 th May

5 Traffic Update 1Q 2017 analysis Average Daily Traffic * Oporto A14 A3 A A1 A1 A2 A3 A4 A5 A6 A9 A10 A12 A13 A14 BCR A10 A9 A5 Lisbon A12 A13 A2 A6 ADT Traffic Growth Rate * (YoY) 12.5% 7.6% 6.0% 5.6% 3.2% 3.5% 1.9% 7.4% 6.4% 1.4% 3.6% 4.4% A1 A2 A3 A4 A5 A6 A9 A10 A12 A13 A14 BCR Positive growth across all network * ADT does not include negative leap year effect 1Q 2017 Traffic update, 15 th May

6

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB

More information

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness

More information

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux

More information

ACACIA PHARMA ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL GLOBAL OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS

ACACIA PHARMA ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL GLOBAL OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS This announcement is an advertisement for the purposes of the Prospectus Rules of the Financial Conduct Authority ( FCA ) and not a prospectus and not an offer of securities for sale in any jurisdiction,

More information

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

World leader in navigated, non-invasive brain stimulation therapy and diagnosis World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

For personal use only

For personal use only Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by

More information

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,

More information

RULES OF CONDUCT OF INSIDERS RESPECTING

RULES OF CONDUCT OF INSIDERS RESPECTING T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )

More information

PLEO-CMT Top-line Results. Presentation October 16, 2018

PLEO-CMT Top-line Results. Presentation October 16, 2018 PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Cavosonstat Phase 2 Trial Results. November 28 th, 2016

Cavosonstat Phase 2 Trial Results. November 28 th, 2016 Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public Incorporation of BVI Business Companies under the BVI Business Companies Act, 2004 1. Introduction The following is a brief summary of the main

More information

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,

More information

Not an Offer for Securities

Not an Offer for Securities Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at presentations to be made by the Company. This presentation does not constitute

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease Dr Bill Ketelbey CEO 17TH ALZHEIMER'S AUSTRALIA BIENNIAL NATIONAL DEMENTIA CONFERENCE 19 OCTOBER 2017 Disclaimer This presentation has

More information

These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017.

These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017. Rules of Membership 1. Introduction These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017. The previously published

More information

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer MagSense Technology A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer Company Overview October 2017 ASX:IBX www.imagionbiosystems.com Disclaimer This presentation has been prepared

More information

Equity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape

Equity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape Member FINRA and SIPC Equity Research November 17, 2017 Healthcare Industry Update Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape Conclusions We hosted a key opinion leader

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

AFFIN HOLDINGS BERHAD (Company No.: W) (Incorporated in Malaysia under the Companies Act, 2016) NOTICE TO SHAREHOLDERS IN RELATION TO THE

AFFIN HOLDINGS BERHAD (Company No.: W) (Incorporated in Malaysia under the Companies Act, 2016) NOTICE TO SHAREHOLDERS IN RELATION TO THE THIS NOTICE IS FOR YOUR INFORMATION ONLY. YOU ARE NOT REQUIRED TO TAKE ANY ACTION. Bursa Malaysia Securities Berhad ( Bursa Securities ) takes no responsibility for the contents of this Notice, makes no

More information

Investor presentation. Bioshares Biotech Summit July 2017

Investor presentation. Bioshares Biotech Summit July 2017 Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available

More information

Dr. Francesco Amato (Italy)

Dr. Francesco Amato (Italy) Dr. Francesco Amato (Italy) Advanced Cadaver Course: Protocols and Guidelines for Immediate Placement in the Anterior Area and Clinical Application of Super-Short Implant May 4 5, 2018 Madrid, Spain Zimmer

More information

TOBACCO INDUSTRY MONITORING TOOL

TOBACCO INDUSTRY MONITORING TOOL TOBACCO INDUSTRY MONITORING TOOL CTCA MakSPH 1 Centre for Tobacco Control in Africa (CTCA) Library Cataloguing - in Publication Data Supporting African governments to build and sustain capacity for tobacco

More information

Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights

Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights Novo Nordisk has proposed to acquire Ablynx for up to 30.50 per share in cash, consisting of 28.00 upfront and 2.50 in Contingent Value Rights Proposal consists of upfront cash consideration of 28.00 per

More information

ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017

ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017 ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017 The ASCAP Screen Music Awards will be held on May 16, 2017. These Official Rules and Regulations (the Rules ) govern the ASCAP Screen Music

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

SWEDISH MATCH RESULTS PRESENTATION Q3 2017 SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

(City, State, Zip Code)

(City, State, Zip Code) This Partner Agency Agreement, dated this day of, 2015, is between COMMUNITY FOOD SHARE, INC. (CFS), whose address is 650 South Taylor Avenue, Louisville, CO 80027, and (Partner Agency) whose address is

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

SAGE-547 s mechanism of action is already addressed by other drugs that are commonly used to treat SRSE patients

SAGE-547 s mechanism of action is already addressed by other drugs that are commonly used to treat SRSE patients April 2016 Sage Therapeutics, Inc. (SAGE) Sell-Side Assumptions Are Wrong: Core Placebo Response Rate Assumption is Way Off and SAGE-547 Still Confers No Meaningful Benefit to SRSE Patients Following our

More information

CSA Briefing Note Regarding Joint Application against the University and Re-Commencing Collection of CFS/CFS-O Fees

CSA Briefing Note Regarding Joint Application against the University and Re-Commencing Collection of CFS/CFS-O Fees CSA Briefing Note Regarding Joint Application against the University and Re-Commencing Collection of CFS/CFS-O Fees The CSA and University of Guelph undergraduate students have been members of the Canadian

More information

Summary Statement of Financial Position (consolidated)

Summary Statement of Financial Position (consolidated) 2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,

More information

MDxHealth. Excellent Buy Opportunity. Research Note.

MDxHealth. Excellent Buy Opportunity. Research Note. Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February

More information

22nd Century Group, Inc. (XXII - $ Buy)

22nd Century Group, Inc. (XXII - $ Buy) Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Infant Bacterial Therapeutics December 2018

Infant Bacterial Therapeutics December 2018 Infant Bacterial Therapeutics December 2018 Disclaimer You must read the following before continuing. The following applies to this document and the information provided in this presentation by Infant

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

PATENCY-1 Top-Line Results

PATENCY-1 Top-Line Results PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,

More information

Important Notices. BASIS CPD Points PN/50971/1516/g

Important Notices. BASIS CPD Points PN/50971/1516/g Chilli pepper results May 2016 1 Important Notices BASIS CPD Points PN/50971/1516/g This document is produced for information only and not in connection with any specific or proposed offer (the Offer )

More information

Bodyweight Pilates Workout Calendar By: Sylvia Favela

Bodyweight Pilates Workout Calendar By: Sylvia Favela Workout Calendar By: Sylvia Favela Copyright Notice No part of this information may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, distributing,

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

Connect with consumers for life. Introducing new MEG-3 Ultra and life sdha Ultra

Connect with consumers for life. Introducing new MEG-3 Ultra and life sdha Ultra Connect with consumers for life Introducing new MEG-3 Ultra and life sdha Ultra ega-3s are essential for everyone, every day Omega-3 fatty acids play a critical role in supporting human health across different

More information

NOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation

NOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation Date 8 August 2017 Sydney, Australia ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Operations Office: Suite 3 Level 4 828 Pacific

More information

ASCAP RHYTHM & SOUL MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017

ASCAP RHYTHM & SOUL MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017 ASCAP RHYTHM & SOUL MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017 The 30th Annual ASCAP Rhythm & Soul Music Awards will be held on June 22, 2017. These Official Rules and Regulations (the Rules ) govern

More information

on the advertising of medicinal products for human use

on the advertising of medicinal products for human use 30. 4. 92 Official Journal of the European Communities No L 113 / 13 COUNCIL DIRECTIVE 92/28/EEC of 31 March 1992 on the advertising of medicinal products for human use THE COUNCIL OF THE EUROPEAN COMMUNITIES,

More information

AR CS205 Clinical Pilot Study Topline Results

AR CS205 Clinical Pilot Study Topline Results AR-13324-CS205 Clinical Pilot Study Topline Results 1 Important Information The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake

More information

THE OPTICAL SOCIETY ONLINE JOURNALS SINGLE SITE LICENSE AGREEMENT

THE OPTICAL SOCIETY ONLINE JOURNALS SINGLE SITE LICENSE AGREEMENT THE OPTICAL SOCIETY ONLINE JOURNALS SINGLE SITE LICENSE AGREEMENT BY THIS AGREEMENT between The Optical Society ( OSA ) and the named below ( Licensee ), OSA grants to Licensee access to the OSA online

More information

Spotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd

Spotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd Spotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given

More information

GENERAL TERMS AND CONDITIONS WCO PUBLICATIONS

GENERAL TERMS AND CONDITIONS WCO PUBLICATIONS Version 1.0 GENERAL TERMS AND CONDITIONS WCO PUBLICATIONS These General Terms and Conditions govern all sales of Publications, on paper and/or in digital format whether directly at the Sales Counter or

More information

ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2019*

ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2019* ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2019* The 27th Annual ASCAP Latin Music Awards will be held on March 5, 2019. These Official Rules and Regulations (the Rules ) govern the ASCAP

More information

Developing Xanamem for Alzheimer s Dementia

Developing Xanamem for Alzheimer s Dementia Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen

More information

4. The time limit, not less than thirty (30) calendar days, for requesting a Hearing in writing.

4. The time limit, not less than thirty (30) calendar days, for requesting a Hearing in writing. SUBJECT: SECTION: CREDENTIALING POLICY NUMBER: CR-05B EFFECTIVE DATE: 04/13 Applies to all products administered by The Plan except when changed by contract Application When the Corporate Credentialing

More information

EKOS. Interventional Vascular 3 February, Imagine where we can go.

EKOS. Interventional Vascular 3 February, Imagine where we can go. EKOS Interventional Vascular 3 February, 2015 Imagine where we can go. Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other

More information

REQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY

REQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY 16 October 2013 Dear Supplier REQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY PHARMAC invites proposals for the supply of nicotine replacement therapy (including, but not limited to, nicotine

More information

ASCAP COUNTRY MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017

ASCAP COUNTRY MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017 ASCAP COUNTRY MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2017 The 55th Annual ASCAP Country Music Awards will be held on November 6, 2017. These Official Rules and Regulations (the Rules ) govern the

More information

ASX Small to Mid Caps New York Conference. March 1, 2012

ASX Small to Mid Caps New York Conference. March 1, 2012 ASX Small to Mid Caps New York Conference March 1, 2012 Important Notice Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at

More information

Morphine capsules retard

Morphine capsules retard Morphine capsules retard, Morphine capsules retard India, Morphine capsules retard manufacturers India, side effects Morphine capsules retard manufacturers, Taj Pharma India, Morphine capsules retard overdose,

More information

Advancing Pancreatic & Liver Cancer Treatment

Advancing Pancreatic & Liver Cancer Treatment ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24 th Melbourne 1 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company)

More information

Employment Contract. This sample employment contract is from Self-Employment vs. Employment Status, CDHA (no date available)

Employment Contract. This sample employment contract is from Self-Employment vs. Employment Status, CDHA (no date available) Employment Contract This sample employment contract is from Self-Employment vs. Employment Status, CDHA (no date available (NOTE: This is only one example of an employment contract. This example is meant

More information

ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018

ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018 ASCAP LATIN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018 The 26th Annual ASCAP Latin Music Awards will be held on March 6, 2018. These Official Rules and Regulations (the Rules ) govern the ASCAP Latin

More information

We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis

We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward

More information

Clinical Review Report (Sample)

Clinical Review Report (Sample) CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) GENERIC DRUG NAME (BRAND NAME) (Manufacturer) Indication: Text Disclaimer: The information in this document is intended to help Canadian health

More information

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology

More information

Hello, Fundraiser! All the best, Julie Lowe Ronald McDonald House Charities of Greater Washington, DC

Hello, Fundraiser! All the best, Julie Lowe Ronald McDonald House Charities of Greater Washington, DC Hello, Fundraiser! We are so excited to work with you on your fundraising event in support of Ronald McDonald House Charities of Greater Washington, DC and help Raise Love for the families we support!

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

THE VILLAGE AT SAVANNAH QUARTERS

THE VILLAGE AT SAVANNAH QUARTERS THE VILLAGE AT SAVANNAH QUARTERS POOLER PARKWAY POOLER, GA 31322 Adam Bryant, CCIM Partner 912.667.2740 adam.bryant@svn.com Tom DeMint, CCIM Partner 843.816.7191 tdemint@svn.com SVN GASC 6001 CHATHAM CENTER

More information

GI Dynamics, Inc. (ASX.GID) Focused on the Patient. Q Shareholder Update

GI Dynamics, Inc. (ASX.GID) Focused on the Patient. Q Shareholder Update Focused on the Patient GI Dynamics, Inc. (ASX.GID) Pioneering treatment for type 2 diabetes /obesity without invasive surgery Q3 2016 Shareholder Update Important Notice Currency References Financial amounts

More information

Standards of Conduct for Transmission Providers

Standards of Conduct for Transmission Providers Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission

More information

For personal use only OSPREY MEDICAL INC EXECUTIVE SUMMARY Q1 2015

For personal use only OSPREY MEDICAL INC EXECUTIVE SUMMARY Q1 2015 OSPREY MEDICAL INC EXECUTIVE SUMMARY Q1 2015 Disclaimer This presentation has been prepared by Osprey Medical, Inc. ( Osprey or the Company ) for the sole purpose of providing general and background information

More information

USPSTF Draft Recommendations Investor Call. October 6, 2015

USPSTF Draft Recommendations Investor Call. October 6, 2015 USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the

More information

ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018*

ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018* ASCAP SCREEN MUSIC AWARDS OFFICIAL RULES AND REGULATIONS 2018* The ASCAP Screen Music Awards will be held on May 23, 2018. These Official Rules and Regulations (the Rules ) govern the ASCAP Screen Music

More information

Constitution for the National Association to Advance Fat Acceptance, Inc. PREAMBLE

Constitution for the National Association to Advance Fat Acceptance, Inc. PREAMBLE Constitution for the National Association to Advance Fat Acceptance, Inc. PREAMBLE The National Association to Advance Fat Acceptance is a nonprofit, member supported organization composed of determined

More information

DISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER

DISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness

More information

Acceptable Use Policy - Phone

Acceptable Use Policy - Phone These terms are current as of August 5, 2017 and are subject to change from time to time. Please visit shaw.ca for the most current Terms of Use. Acceptable Use Policy - Phone Introduction Thank you for

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Analyst Report Written by Mark Bonacci, Chief Financial Analyst

Analyst Report Written by Mark Bonacci, Chief Financial Analyst Analyst Report Written by Mark Bonacci, Chief Financial Analyst Mark Bonacci has worked on Wall Street for several years in various financial services roles and is a selfemployed investment analyst and

More information

Government Gazette REPUBLIC OF SOUTH AFRICA

Government Gazette REPUBLIC OF SOUTH AFRICA Government Gazette REPUBLIC OF SOUTH AFRICA Vol. 523 Cape Town 9 January 2009 No. 31790 THE PRESIDENCY No. 23 9 January 2009 It is hereby notified that the President has assented to the following Act,

More information

Release & Waiver Synergy Studio

Release & Waiver Synergy Studio Release & Waiver Synergy Studio I,, have enrolled in a program of physical activity, including but not limited to, body conditioning machinery used during the workouts offered by Synergy Studio. I affirm

More information

MDxHealth. AssureMDx leaves competition behind. Research Note.

MDxHealth. AssureMDx leaves competition behind. Research Note. Research Note MDxHealth AssureMDx leaves competition behind Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date:

More information

Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018

Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018 Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018 Disclaimer This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ( Company

More information

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about

More information

How Well Are You Thinking?

How Well Are You Thinking? How Well Are You Thinking? Please complete this form in ink without the assistance of others. Name Date of Birth / / How far did you get in school? I am a Man Woman I am NZ European Māori P acific Islander

More information

NORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director

NORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director Robert Ullman Managing Director rullman@dinancapital.com 45.63.44 NORTH AMERICAN DERMATOLOGY M&A Activity and Valuation Trends Q4 205 William Downing Director wdowning@dinancapital.com 602.734.0682 Michael

More information

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical

More information

Diagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014

Diagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014 Diagnostics for the early detection and prevention of colon cancer Publication of DeeP-C Study Data in New England Journal of Medicine March 2014 Safe Harbor Statement Certain statements made in this presentation

More information

Presentation to 2019 JP Morgan Healthcare Conference

Presentation to 2019 JP Morgan Healthcare Conference For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,

More information

The Lipid Metabolism Company. Corporate Presentation March 2018

The Lipid Metabolism Company. Corporate Presentation March 2018 The Lipid Metabolism Company Corporate Presentation March 2018 Disclaimer This document has been prepared by Cerenis Therapeutics (the "Company") and is for information purposes only. The information and

More information

ORDINANCE NO

ORDINANCE NO ORDINANCE NO. 01-2017 AN ORDINANCE OF THE CITY COUNCIL OF THE CITY OF SEMINOLE, FLORIDA, REGARDING MEDICAL CANNABIS; IMPOSING A TEMPORARY MORATORIUM ON THE SALE OF MEDICAL CANNABIS AND ON THE ESTABLISHMENT

More information

Annual Results 2017 & Business Update 13 April 2018

Annual Results 2017 & Business Update 13 April 2018 Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject

More information

(English text signed by the State President) as amended by

(English text signed by the State President) as amended by TOBACCO PRODUCTS CONTROL ACT 83 OF 1993 [ASSENTED TO 23 JUNE 1993] [DATE OF COMMENCEMENT: 1 FEBRUARY 1994] (English text signed by the State President) as amended by General Law Fifth Amendment Act 157

More information

Presentation of. Burgdorf, 1 st November 2012

Presentation of. Burgdorf, 1 st November 2012 Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,

More information

MDxHealth. Strong outlook for Research Note.

MDxHealth. Strong outlook for Research Note. Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February

More information

ORDINANCE NO

ORDINANCE NO ORDINANCE NO. 2017-06 AN ORDINANCE OF THE CITY OF LABELLE, FLORIDA; ESTABLISHING A TEMPORARY MORATORIUM OF TWO HUNDRED AND SEVENTY DAYS (270) PROHIBITING THE OPERATION OF ANY MEDICAL MARIJUANA FACILITIES

More information

Mental Toronto Hydro

Mental Toronto Hydro Mental Health @ Shirley Powell, Director, HR Planning, Systems & Rewards Benefits Canada s 2015 Healthy Outcomes Conference June 9-11, 2015 Niagara-on-the-Lake Company Overview Established in 1911 Largest

More information

Model 380B DNA Synthesizer Version 1.1

Model 380B DNA Synthesizer Version 1.1 Model 380B DNA Synthesizer Version 1.1 User s Manual Copyright 2001, Applied Biosystems. All rights reserved. For Research Use Only. Not for use in diagnostic procedures. APPLIED BIOSYSTEMS LIMITED WARRANTY

More information